BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

632 related articles for article (PubMed ID: 32722796)

  • 1. Gain-of-function mutant p53 in cancer progression and therapy.
    Zhang C; Liu J; Xu D; Zhang T; Hu W; Feng Z
    J Mol Cell Biol; 2020 Sep; 12(9):674-687. PubMed ID: 32722796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy.
    Yue X; Zhao Y; Xu Y; Zheng M; Feng Z; Hu W
    J Mol Biol; 2017 Jun; 429(11):1595-1606. PubMed ID: 28390900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gain of function mutant p53 protein activates AKT through the Rac1 signaling to promote tumorigenesis.
    Yue X; Wu F; Li Y; Liu J; Boateng M; Mandava K; Zhang C; Feng Z; Gao J; Hu W
    Cell Cycle; 2020 Jun; 19(11):1338-1351. PubMed ID: 32275841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutant p53 in Cancer Progression and Targeted Therapies.
    Zhu G; Pan C; Bei JX; Li B; Liang C; Xu Y; Fu X
    Front Oncol; 2020; 10():595187. PubMed ID: 33240819
    [No Abstract]   [Full Text] [Related]  

  • 5. The ubiquitin ligase TRIM21 regulates mutant p53 accumulation and gain of function in cancer.
    Liu J; Zhang C; Xu D; Zhang T; Chang CY; Wang J; Liu J; Zhang L; Haffty BG; Zong WX; Hu W; Feng Z
    J Clin Invest; 2023 Mar; 133(6):. PubMed ID: 36749630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutant p53 in cancer: from molecular mechanism to therapeutic modulation.
    Chen X; Zhang T; Su W; Dou Z; Zhao D; Jin X; Lei H; Wang J; Xie X; Cheng B; Li Q; Zhang H; Di C
    Cell Death Dis; 2022 Nov; 13(11):974. PubMed ID: 36400749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation.
    Kong LR; Ong RW; Tan TZ; Mohamed Salleh NAB; Thangavelu M; Chan JV; Koh LYJ; Periyasamy G; Lau JA; Le TBU; Wang L; Lee M; Kannan S; Verma CS; Lim CM; Chng WJ; Lane DP; Venkitaraman A; Hung HT; Cheok CF; Goh BC
    Nat Commun; 2020 Apr; 11(1):2086. PubMed ID: 32350249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pontin, a new mutant p53-binding protein, promotes gain-of-function of mutant p53.
    Zhao Y; Zhang C; Yue X; Li X; Liu J; Yu H; Belyi VA; Yang Q; Feng Z; Hu W
    Cell Death Differ; 2015 Nov; 22(11):1824-36. PubMed ID: 25857266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BAG2 promotes tumorigenesis through enhancing mutant p53 protein levels and function.
    Yue X; Zhao Y; Liu J; Zhang C; Yu H; Wang J; Zheng T; Liu L; Li J; Feng Z; Hu W
    Elife; 2015 Aug; 4():. PubMed ID: 26271008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spliced MDM2 isoforms promote mutant p53 accumulation and gain-of-function in tumorigenesis.
    Zheng T; Wang J; Zhao Y; Zhang C; Lin M; Wang X; Yu H; Liu L; Feng Z; Hu W
    Nat Commun; 2013; 4():2996. PubMed ID: 24356649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From mutational inactivation to aberrant gain-of-function: Unraveling the structural basis of mutant p53 oncogenic transition.
    Olotu FA; Soliman MES
    J Cell Biochem; 2018 Mar; 119(3):2646-2652. PubMed ID: 29058783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour-associated mutant p53 drives the Warburg effect.
    Zhang C; Liu J; Liang Y; Wu R; Zhao Y; Hong X; Lin M; Yu H; Liu L; Levine AJ; Hu W; Feng Z
    Nat Commun; 2013; 4():2935. PubMed ID: 24343302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gain-of-function miRNA signature by mutant p53 associates with poor cancer outcome.
    Zhang Y; Hu Y; Fang JY; Xu J
    Oncotarget; 2016 Mar; 7(10):11056-66. PubMed ID: 26840456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities.
    Iyer SV; Parrales A; Begani P; Narkar A; Adhikari AS; Martinez LA; Iwakuma T
    Oncotarget; 2016 Feb; 7(5):5401-15. PubMed ID: 26700961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutant p53 drives the loss of heterozygosity by the upregulation of Nek2 in breast cancer cells.
    Ghaleb A; Padellan M; Marchenko N
    Breast Cancer Res; 2020 Dec; 22(1):133. PubMed ID: 33267874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target.
    Schulz-Heddergott R; Moll UM
    Cancers (Basel); 2018 Jun; 10(6):. PubMed ID: 29875343
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Pan M; Jiang C; Tse P; Achacoso N; Alexeeff S; Solorzano AV; Chung E; Hu W; Truong TG; Arora A; Sundaresan T; Suga JM; Thomas S; Habel LA
    J Clin Oncol; 2022 Jan; 40(2):171-179. PubMed ID: 34843402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant p53 in cancer therapy-the barrier or the path.
    Zhou X; Hao Q; Lu H
    J Mol Cell Biol; 2019 Apr; 11(4):293-305. PubMed ID: 30508182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion.
    Schulz-Heddergott R; Stark N; Edmunds SJ; Li J; Conradi LC; Bohnenberger H; Ceteci F; Greten FR; Dobbelstein M; Moll UM
    Cancer Cell; 2018 Aug; 34(2):298-314.e7. PubMed ID: 30107178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gain-of-Function Mutant p53: All the Roads Lead to Tumorigenesis.
    Stein Y; Rotter V; Aloni-Grinstein R
    Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.